Morgan Stanley’s Oncolytics Biotech ONCY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $23.8K | Sell |
27,987
-398,531
| -93% | -$396K | ﹤0.01% | 6662 |
|
|
2025
Q4 | $373K | Buy |
426,518
+43,172
| +11% | +$46.7K | ﹤0.01% | 5666 |
|
|
2025
Q3 | $537K | Buy |
383,346
+364,493
| +1,933% | +$408K | ﹤0.01% | 5469 |
|
|
2025
Q2 | $14.6K | Buy |
18,853
+1,500
| +9% | +$795 | ﹤0.01% | 6749 |
|
|
2025
Q1 | $9.54K | Sell |
17,353
-5,500
| -24% | -$4.02K | ﹤0.01% | 6814 |
|
|
2024
Q4 | $20.9K | Sell |
22,853
-3,689
| -14% | -$3.84K | ﹤0.01% | 6560 |
|
|
2024
Q3 | $23.1K | Sell |
26,542
-111,979
| -81% | -$110K | ﹤0.01% | 6460 |
|
|
2024
Q2 | $137K | Sell |
138,521
-209,792
| -60% | -$228K | ﹤0.01% | 5844 |
|
|
2024
Q1 | $369K | Sell |
348,313
-114,457
| -25% | -$128K | ﹤0.01% | 5450 |
|
|
2023
Q4 | $625K | Buy |
462,770
+400,276
| +641% | +$626K | ﹤0.01% | 5528 |
|
|
2023
Q3 | $136K | Sell |
62,494
-121,719
| -66% | -$297K | ﹤0.01% | 5741 |
|
|
2023
Q2 | $479K | Buy |
184,213
+77,228
| +72% | +$128K | ﹤0.01% | 5236 |
|
|
2023
Q1 | $128K | Buy |
106,985
+2,775
| +3% | +$4.36K | ﹤0.01% | 5912 |
|
|
2022
Q4 | $170K | Buy |
104,210
+5,732
| +6% | +$8.7K | ﹤0.01% | 5738 |
|
|
2022
Q3 | $121K | Buy |
98,478
+6,587
| +7% | +$8.07K | ﹤0.01% | 5983 |
|
|
2022
Q2 | $93K | Buy |
91,891
+32,526
| +55% | +$39.6K | ﹤0.01% | 6313 |
|
|
2022
Q1 | $94K | Sell |
59,365
-28,185
| -32% | -$47.3K | ﹤0.01% | 6351 |
|
|
2021
Q4 | $122K | Buy |
87,550
+4,398
| +5% | +$8.13K | ﹤0.01% | 6321 |
|
|
2021
Q3 | $174K | Buy |
83,152
+36,874
| +80% | +$83.5K | ﹤0.01% | 6073 |
|
|
2021
Q2 | $128K | Sell |
46,278
-4,700
| -9% | -$14.4K | ﹤0.01% | 6235 |
|
|
2021
Q1 | $194K | Buy |
50,978
+13,431
| +36% | +$40.1K | ﹤0.01% | 5675 |
|
|
2020
Q4 | $90K | Buy |
37,547
+14,270
| +61% | +$34.2K | ﹤0.01% | 5956 |
|
|
2020
Q3 | $40K | Buy |
23,277
+4,448
| +24% | +$8.16K | ﹤0.01% | 5801 |
|
|
2020
Q2 | $35K | Buy |
18,829
+15,117
| +407% | +$28.5K | ﹤0.01% | 5807 |
|
|
2020
Q1 | $5K | Sell |
3,712
-136,566
| -97% | -$341K | ﹤0.01% | 6217 |
|
|
2019
Q4 | $668K | Sell |
140,278
-62,731
| -31% | -$70.8K | ﹤0.01% | 4764 |
|
|
2019
Q3 | $115K | Buy |
203,009
+146,549
| +260% | +$149K | ﹤0.01% | 5392 |
|
|
2019
Q2 | $97K | Buy |
56,460
+8,476
| +18% | +$15.4K | ﹤0.01% | 5339 |
|
|
2019
Q1 | $89K | Sell |
47,984
-5,100
| -10% | -$10.3K | ﹤0.01% | 5438 |
|
|
2018
Q4 | $96K | Sell |
53,084
-260
| -0.5% | -$704 | ﹤0.01% | 5574 |
|
|
2018
Q3 | $206K | Buy |
53,344
+6,362
| +14% | +$29.6K | ﹤0.01% | 5446 |
|
|
2018
Q2 | $258K | Buy |
+46,982
| New | +$289K | ﹤0.01% | 5443 |
|
Other funds holding ONCY
SFP
SI
TAM
EFG
XT
DA
Morgan Stanley's ONCY Position: Q1 2026 in Review
Morgan Stanley reduced its Oncolytics Biotech (ONCY) stake by 93% in Q1 2026, selling an estimated $396K and leaving 27,987 shares worth $23.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6662.
Morgan Stanley first reported a position in ONCY in Q2 2018 and has held it in 32 quarters since. The position peaked at $668K in Q4 2019. 59 funds tracked by Wall St. Rank hold ONCY as of Q1 2026.
- Morgan Stanley held 27,987 shares of Oncolytics Biotech worth $23.8K as of Q1 2026.
- Morgan Stanley sold 398,531 Oncolytics Biotech shares in Q1 2026, an estimated $396K.
- Oncolytics Biotech made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6662 holding.
- Morgan Stanley first reported a position in Oncolytics Biotech in Q2 2018 and has held it in 32 quarters since.
- Morgan Stanley's Oncolytics Biotech position peaked at $668K in Q4 2019.
- 59 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.